Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KYV 101

Next Previous
X
Search
Drug Profile

KYV 101

Alternative Names: Autologous anti-CD19 CAR T cell therapy - Kyverna Therapeutics; KYV-101

Latest Information Update: 30 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Kyverna Therapeutics; National Institutes of Health (USA)
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis; Myasthenia gravis; Stiff-person syndrome
  • Phase I/II Lupus nephritis; Systemic scleroderma

Most Recent Events

  • 30 Sep 2024 Kyverna Therapeutics plans a phase I/II trial for Vasculitis (IV, infusion) in January 2025 (NCT06590545)
  • 19 Sep 2024 Phase-II clinical trials in Stiff-person syndrome (Treatment-resistant) in USA (Parenteral) (NCT06588491)
  • 28 Aug 2024 Phase-II clinical trials in Myasthenia gravis (Treatment-resistant) in Germany (Parenteral) (NCT06193889)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top